Menu Search
Equities

Medicus Pharma Ltd

N460:FRA

Medicus Pharma Ltd

Actions
  • Price (EUR)2.73
  • Today's Change0.00 / 0.00%
  • Shares traded400.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 12:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-16.39m
  • Incorporated2008
  • Employees--
  • Location
    Medicus Pharma Ltd100 King Street West, Suite 3400TORONTO M5X 1A4CanadaCAN
  • Phone+1 (905) 681-1925
  • Fax+1 (905) 681-1925
  • Websitehttps://medicuspharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.